215 related articles for article (PubMed ID: 35061305)
1. FOXO1 cooperates with C/EBPδ and ATF4 to regulate skeletal muscle atrophy transcriptional program during fasting.
Oyabu M; Takigawa K; Mizutani S; Hatazawa Y; Fujita M; Ohira Y; Sugimoto T; Suzuki O; Tsuchiya K; Suganami T; Ogawa Y; Ishihara K; Miura S; Kamei Y
FASEB J; 2022 Feb; 36(2):e22152. PubMed ID: 35061305
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
3. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy.
Milan G; Romanello V; Pescatore F; Armani A; Paik JH; Frasson L; Seydel A; Zhao J; Abraham R; Goldberg AL; Blaauw B; DePinho RA; Sandri M
Nat Commun; 2015 Apr; 6():6670. PubMed ID: 25858807
[TBL] [Abstract][Full Text] [Related]
4. cAMP-dependent protein kinase inhibits FoxO activity and regulates skeletal muscle plasticity in mice.
Silveira WA; Gonçalves DA; Machado J; Lautherbach N; Lustrino D; Paula-Gomes S; Pereira MG; Miyabara EH; Sandri M; Kettelhut IC; Navegantes LC
FASEB J; 2020 Sep; 34(9):12946-12962. PubMed ID: 32772437
[TBL] [Abstract][Full Text] [Related]
5. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Xu J; Li R; Workeneh B; Dong Y; Wang X; Hu Z
Kidney Int; 2012 Aug; 82(4):401-11. PubMed ID: 22475820
[TBL] [Abstract][Full Text] [Related]
6. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction.
Schulze PC; Fang J; Kassik KA; Gannon J; Cupesi M; MacGillivray C; Lee RT; Rosenthal N
Circ Res; 2005 Sep; 97(5):418-26. PubMed ID: 16051886
[TBL] [Abstract][Full Text] [Related]
7. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth.
Lee D; Goldberg AL
J Biol Chem; 2013 Oct; 288(42):30515-30526. PubMed ID: 24003218
[TBL] [Abstract][Full Text] [Related]
8. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.
Sandri M; Sandri C; Gilbert A; Skurk C; Calabria E; Picard A; Walsh K; Schiaffino S; Lecker SH; Goldberg AL
Cell; 2004 Apr; 117(3):399-412. PubMed ID: 15109499
[TBL] [Abstract][Full Text] [Related]
9. The cathepsin L gene is a direct target of FOXO1 in skeletal muscle.
Yamazaki Y; Kamei Y; Sugita S; Akaike F; Kanai S; Miura S; Hirata Y; Troen BR; Kitamura T; Nishino I; Suganami T; Ezaki O; Ogawa Y
Biochem J; 2010 Mar; 427(1):171-8. PubMed ID: 20088826
[TBL] [Abstract][Full Text] [Related]
10. Advanced glycation end products induce skeletal muscle atrophy and insulin resistance via activating ROS-mediated ER stress PERK/FOXO1 signaling.
Du H; Ma Y; Wang X; Zhang Y; Zhu L; Shi S; Pan S; Liu Z
Am J Physiol Endocrinol Metab; 2023 Mar; 324(3):E279-E287. PubMed ID: 36724125
[TBL] [Abstract][Full Text] [Related]
11. Obestatin controls the ubiquitin-proteasome and autophagy-lysosome systems in glucocorticoid-induced muscle cell atrophy.
Cid-Díaz T; Santos-Zas I; González-Sánchez J; Gurriarán-Rodríguez U; Mosteiro CS; Casabiell X; García-Caballero T; Mouly V; Pazos Y; Camiña JP
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):974-990. PubMed ID: 28675664
[TBL] [Abstract][Full Text] [Related]
12. Excessive glucocorticoid-induced muscle MuRF1 overexpression is independent of Akt/FoXO1 pathway.
Wang XJ; Xiao JJ; Liu L; Jiao HC; Lin H
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29046370
[TBL] [Abstract][Full Text] [Related]
13.
Lee MK; Choi JW; Choi YH; Nam TJ
Mar Drugs; 2018 Dec; 16(12):. PubMed ID: 30544821
[TBL] [Abstract][Full Text] [Related]
14. Stress-induced skeletal muscle Gadd45a expression reprograms myonuclei and causes muscle atrophy.
Ebert SM; Dyle MC; Kunkel SD; Bullard SA; Bongers KS; Fox DK; Dierdorff JM; Foster ED; Adams CM
J Biol Chem; 2012 Aug; 287(33):27290-301. PubMed ID: 22692209
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
16. FoxO Transcription Factors Are Critical Regulators of Diabetes-Related Muscle Atrophy.
O'Neill BT; Bhardwaj G; Penniman CM; Krumpoch MT; Suarez Beltran PA; Klaus K; Poro K; Li M; Pan H; Dreyfuss JM; Nair KS; Kahn CR
Diabetes; 2019 Mar; 68(3):556-570. PubMed ID: 30523026
[TBL] [Abstract][Full Text] [Related]
17. Effects of fenofibrate and its combination with lovastatin on the expression of genes involved in skeletal muscle atrophy, including FoxO1 and its targets.
Ajima H; Kai Y; Fujimaki J; Akashi S; Morita A; Ezaki O; Kamei Y; Miura S
J Toxicol Sci; 2021; 46(1):11-24. PubMed ID: 33408297
[TBL] [Abstract][Full Text] [Related]
18. Regulation of muscle atrophy-related genes by the opposing transcriptional activities of ZEB1/CtBP and FOXO3.
Ninfali C; Siles L; Darling DS; Postigo A
Nucleic Acids Res; 2018 Nov; 46(20):10697-10708. PubMed ID: 30304480
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.
Reed SA; Sandesara PB; Senf SM; Judge AR
FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632
[TBL] [Abstract][Full Text] [Related]
20. FOXO1 suppresses PGC-1β gene expression in skeletal muscles.
Nakai S; Oyabu M; Hatazawa Y; Akashi S; Kitamura T; Miura S; Kamei Y
FEBS Open Bio; 2020 Jul; 10(7):1373-1388. PubMed ID: 32433820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
